Back to Search
Start Over
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
- Source :
- Acta Dermato-Venereologica, Vol 101, Iss 11 (2021)
- Publication Year :
- 2021
- Publisher :
- Medical Journals Sweden, 2021.
-
Abstract
- Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life. Post-hoc analyses of a 1-year, randomized, double-blinded, placebo- controlled trial (NCT02260986) of dupilumab with concomitant topical corticosteroids in 421 adults with moderate-to-severe atopic dermatitis (of whom 315/106 received placebo/dupilumab (of whom 315 received placebo and 106 received dupilumab) was performed to assess the proportion of responders to dupilumab through a multidimensional composite endpoint. At 6-months, 80.2% of dupilumab-treated vs 40.0% placebo patients (p
Details
- Language :
- English
- ISSN :
- 00015555 and 16512057
- Volume :
- 101
- Issue :
- 11
- Database :
- Directory of Open Access Journals
- Journal :
- Acta Dermato-Venereologica
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.533ab1ccbbd94b2b91b12b77601f1e28
- Document Type :
- article
- Full Text :
- https://doi.org/10.2340/actadv.v101.307